Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Evenamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 11/20 | 0.98 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Evenamide SCHEMBL29409440 | 1.00 | KCNH2 (1.00) | KCNH2CYP2D6CACNA1B | |
| Evenamide SCHEMBL29389974 | 0.99 | CYP2D6 (1.00) | KCNH2CYP2D6CACNA1B | |
| Evenamide SCHEMBL3025285 | 0.99 | CYP2D6 (1.00) | KCNH2CYP2D6CACNA1B | |
| Hydrochloric Acid SCHEMBL3023611 | 0.97 | KCNH2 (1.00) | KCNH2CYP2D6CACNA1B | |
| Hydrochloric Acid SCHEMBL3026806 | 0.95 | CYP2D6 (0.98) | KCNH2CYP2D6CACNA1B | |
| SCHEMBL3028517 | 0.95 | CYP2D6 (1.00) | KCNH2CYP2D6CACNA1B | |
| SCHEMBL3023656 | 0.94 | CYP2D6 (1.00) | KCNH2CYP2D6CACNA1B | |
| SCHEMBL3637666 | 0.94 | CYP2D6 (1.00) | KCNH2CYP2D6CACNA1B | |
| SCHEMBL3635823 | 0.92 | CYP2D6 (0.88) | KCNH2CYP2D6CACNA1B | |
| Hydrochloric Acid SCHEMBL3032627 | 0.91 | CYP2D6 (0.98) | KCNH2CYP2D6CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257031-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL)ETHYLAMINO]ALKANEAMIDE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2025-08-14 | — | — | US | disclosed |
| US-12291495-B2 | Process for the production of substituted 2-[2-(phenyl)ethylamino] alkaneamide derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2025-05-06 | — | — | US | disclosed |
| US-12134589-B2 | Process for the production of substituted 2-[2-(phenyl) ethylaminojalkaneamide derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2024-11-05 | — | — | US | disclosed |
| US-20220185766-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL)ETHYLAMINO]ALKANEAMIDE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2022-06-16 | — | — | US | disclosed |
| US-20220177417-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO]ALKANEAMIDE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2022-06-09 | — | — | US | disclosed |
| EP-3956296-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO]ALKANEAMIDE DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2022-02-23 | — | — | EP | disclosed |
| EP-3956295-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO]ALKANEAMIDE DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2022-02-23 | — | — | EP | disclosed |
| WO-2020212227-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO]ALKANEAMIDE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020212352-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO]ALKANEAMIDE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2020-10-22 | — | — | WO | disclosed |
| EP-3725769-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO]ALKANEAMIDE DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2020-10-21 | — | — | EP | disclosed |
| US-20150157598-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2015-06-11 | — | — | US | disclosed |
| US-9051240-B2 | Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2015-06-09 | — | — | US | disclosed |
| CN-101687773-B | Substituted 2- [2- (phenyl) ethylamino ] alkanamide derivatives and their use as sodium and/or calcium channel modulators | NEWRON PHARM SPA | 2014-07-30 | — | — | CN | disclosed |
| US-20130289122-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A (IT) | 2013-10-31 | — | — | US | disclosed |
| US-20130274249-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A (IT) | 2013-10-17 | — | — | US | disclosed |
| US-8519000-B2 | Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2013-08-27 | — | — | US | disclosed |
| US-20100210631-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-08-19 | — | — | US | disclosed |
| CN-101687773-A | Substituted 2- [ 2- (phenyl) ethylamino ] alkanamide derivatives and their use as sodium and/or calcium channel modulators | NEWRON PHARM SPA | 2010-03-31 | — | — | CN | disclosed |
| EP-2155663-A1 | SUBSTITUTED 2- Ý2- (PHENYL) ETHYLAMINO¨ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | Newron Pharmaceuticals S.p.A. (IT) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008151702-A1 | SUBSTITUTED 2- [2- (PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12134589-B2 | Process for the production of substituted 2-[2-(phenyl) ethylaminojalkaneamide derivatives | BCKDK, PKD2, ADCK5 | KCNH2 190/4885CYP2D6 170/4885CACNA1B 267/4885 |
| US-20130274249-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | CACNA1A, CACNA1B, SARAF | KCNH2 174/4885CYP2D6 3287/4885CACNA1B 2/4885 |
| US-20220185766-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL)ETHYLAMINO]ALKANEAMIDE DERIVATIVES | HRH3, CYP2A7, HRH4 | KCNH2 297/4885CYP2D6 116/4885CACNA1B 1530/4885 |
| US-20250257031-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL)ETHYLAMINO]ALKANEAMIDE DERIVATIVES | HRH3, HRH4, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | KCNH2 188/4885CYP2D6 56/4885CACNA1B 1166/4885 |
| US-12291495-B2 | Process for the production of substituted 2-[2-(phenyl)ethylamino] alkaneamide derivatives | HRH3, CYP2A7, HRH4 | KCNH2 297/4885CYP2D6 116/4885CACNA1B 1530/4885 |
| US-20150157598-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | CACNA1A, CACNA1E, CACNA1S | KCNH2 105/4885CYP2D6 2275/4885CACNA1B 5/4885 |
| US-20100210631-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | CACNA1A, CACNA1B, SARAF | KCNH2 169/4885CYP2D6 3284/4885CACNA1B 2/4885 |
| US-20130289122-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | CACNA1A, CACNA1B, SARAF | KCNH2 174/4885CYP2D6 3287/4885CACNA1B 2/4885 |
| US-20220177417-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO]ALKANEAMIDE DERIVATIVES | PKD2, BCKDK, ALK | KCNH2 143/4885CYP2D6 320/4885CACNA1B 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.